title: Vascular endothelial growth factor (VEGF) gene polymorphisms and breast cancer risk in Punjabi population from North West India.
abstract: The purpose of this study was to evaluate the association of seven VEGF promoter polymorphisms with breast cancer risk in Punjabi population from North West India. We screened DNA samples of 102 sporadic breast cancer patients and 102 unrelated healthy, gender, and age-matched individuals for seven VEGF promoter polymorphisms [-417 C/T (rs833062), -172 C/A (rs59260042), -165 C/T (rs79469752), -160 C/T, -152 G/A (rs13207351), -141 A/C (rs28357093) and -116 G/A (rs1570360)] by direct sequencing. The frequency of GG, GA, and AA genotype of -152 G/A polymorphism was 26.47 vs 38.34%, 46.08 vs 51.96%, and 27.45 vs 9.80%, in patients and controls, respectively. VEGF -152 AA genotype was significantly associated with increased risk for breast cancer (OR = 4.04, 95%CI, 1.69-9.68, p = 0.001; recessive model OR = 3.48, 95%CI, 1.59-7.63, p = 0.001). For VEGF -116 G/A polymorphism, G and A allele frequencies were 65.2 vs 76.47% and 34.8 vs 23.53% in patients and controls, respectively. Individuals having -116 AA genotype (OR = 3.40; 95%CI, 1.24-9.37; p = 0.014) and A allele (OR = 1.73; 95%CI, 1.12-2.67; p = 0.012) were associated with increased risk for breast cancer. VEGF -165 C/T and -141 A/C polymorphisms were associated with reduced risk for breast cancer. There was significantly decreased frequency of CT genotype (4.90 vs 18.63%; p = 0.002) and T allele (2.45 vs 9.31%; p = 0.003) of -165 C/T polymorphism among breast cancer patients as compared to controls. VEGF -141 A and C allele frequency were 96.57 vs 91.18% and 3.43 vs 8.82% in patients and controls, respectively. Significant reduced risk for breast cancer was observed with AC genotype (OR = 0.34, 95%CI, 0.14-0.86; p = 0.019) and C allele (OR = 0.37; 95%CI, 0.15-0.89; p = 0.023) of -141 A/C polymorphism. We did not observe association of VEGF -417 T/C, -172 C/A, -160 C/T polymorphisms with breast cancer risk in the studied subjects (p > 0.05). The VEGF -152 G/A and -116 G/A polymorphisms were found to be significantly associated with increased risk for breast cancer while -165 C/T and -141 A/C polymorphisms were found to be associated with decreased risk for breast cancer in Punjabi population from North West India.
authors.affiliation: Human Cytogenetics Laboratory, Department of Human Genetics, Guru Nanak Dev University, Amritsar, 143005, Punjab, India, kapahiruhi@yahoo.com.
authors.forename: Ruhi
authors.initials: R
authors.lastname: Kapahi
authors.forename: Kamlesh
authors.initials: K
authors.lastname: Guleria
authors.forename: Vasudha
authors.initials: V
authors.lastname: Sambyal
authors.forename: Mridu
authors.initials: M
authors.lastname: Manjari
authors.forename: Meena
authors.initials: M
authors.lastname: Sudan
authors.forename: Manjit Singh
authors.initials: MS
authors.lastname: Uppal
authors.forename: Neeti Rajan
authors.initials: NR
authors.lastname: Singh
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007194:India; D008875:Middle Aged; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A
references.citation: J Mol Biol. 1999 Oct 22;293(2):199-213
references.pmid: 10550204
references.citation: Int J Cancer. 2000 Nov 20;89(6):475-83
references.pmid: 11102890
references.citation: Am J Reprod Immunol. 2008 Apr;59(4):301-5
references.pmid: 18294357
references.citation: Fertil Steril. 2005 Apr;83(4):959-63
references.pmid: 15820807
references.citation: Nat Genet. 1999 May;22(1):59-62
references.pmid: 10319862
references.citation: Hum Reprod. 2012 May;27(5):1536-41
references.pmid: 22402207
references.citation: Nat Rev Cancer. 2002 Oct;2(10):795-803
references.pmid: 12360282
references.citation: Am J Hum Genet. 2001 Jul;69(1):124-37
references.pmid: 11404818
references.citation: Mol Carcinog. 2005 Jun;43(2):65-74
references.pmid: 15768385
references.citation: Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3611-6
references.pmid: 18441306
references.citation: Breast Cancer Res. 2006;8(2):R22
references.pmid: 16613616
references.citation: Lancet. 2004 Jan 10;363(9403):157-63
references.pmid: 14726171
references.citation: Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1745-55
references.pmid: 22892282
references.citation: Mol Med Rep. 2009 May-Jun;2(3):435-9
references.pmid: 21475847
references.citation: Nat Genet. 2000 Jul;25(3):320-3
references.pmid: 10888882
references.citation: Hum Immunol. 1999 Dec;60(12):1245-9
references.pmid: 10626738
references.citation: Lung Cancer. 2004 Dec;46(3):293-8
references.pmid: 15541813
references.citation: Pharmacogenomics. 2007 Jan;8(1):49-66
references.pmid: 17187509
references.citation: Neurosci Lett. 2009 Jul 3;457(3):133-6
references.pmid: 19429179
references.citation: Asian Pac J Cancer Prev. 2013;14(1):523-8
references.pmid: 23534787
references.citation: Asian Pac J Cancer Prev. 2013;14(1):183-8
references.pmid: 23534721
references.citation: Nat Genet. 2003 Aug;34(4):383-94
references.pmid: 12847526
references.citation: Genes Immun. 2002 Jun;3(4):229-32
references.pmid: 12058259
references.citation: Int J Gynecol Cancer. 2010 Jul;20(5):717-23
references.pmid: 20973260
references.citation: Circulation. 1996 Apr 15;93(8):1493-5
references.pmid: 8608615
references.citation: Breast. 2004 Apr;13(2):85-92
references.pmid: 15019686
references.citation: J Vasc Res. 2000 Nov-Dec;37(6):443-8
references.pmid: 11146397
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: Reprod Biomed Online. 2011 Jan;22(1):59-64
references.pmid: 21126911
references.citation: Asian Pac J Cancer Prev. 2012;13(1):139-46
references.pmid: 22502657
references.citation: Breast Cancer Res Treat. 2012 Jun;133(3):1097-104
references.pmid: 22350789
references.citation: Clin Cancer Res. 2005 May 15;11(10):3647-53
references.pmid: 15897560
references.citation: Asian Pac J Cancer Prev. 2012;13(5):1949-52
references.pmid: 22901152
references.citation: Oncol Rep. 2002 May-Jun;9(3):455-60
references.pmid: 11956609
references.citation: Nat Rev Cancer. 2004 Aug;4(8):579-91
references.pmid: 15286738
references.citation: Mol Med Rep. 2013 Oct;8(4):1242-50
references.pmid: 23904001
references.citation: Cytokine. 2000 Aug;12(8):1232-5
references.pmid: 10930302
references.citation: Am J Epidemiol. 1999 Dec 15;150(12):1316-24
references.pmid: 10604774
references.citation: Eur J Surg Oncol. 2011 Jan;37(1):93-9
references.pmid: 21093207
references.citation: Mol Cell Biol. 1998 Jun;18(6):3112-9
references.pmid: 9584152
references.citation: Clin Chem. 1990 Feb;36(2):261-4
references.pmid: 1967986
references.citation: J Eur Acad Dermatol Venereol. 2013 Mar;27(3):319-23
references.pmid: 22176586
references.citation: Int J Oncol. 1998 Mar;12(3):541-4
references.pmid: 9472090
references.citation: Genet Mol Res. 2012 Dec 21;11(4):4739-45
references.pmid: 23315815
references.citation: Mol Vis. 2011;17:3088-96
references.pmid: 22162628
references.citation: Asian Pac J Cancer Prev. 2012;13(8):3637-43
references.pmid: 23098447
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):675-82
references.pmid: 16614108
references.citation: Nature. 2005 Dec 15;438(7070):932-6
references.pmid: 16355210
references.citation: Nat Clin Pract Oncol. 2007 Mar;4(3):181-9
references.pmid: 17327858
references.citation: Nat Genet. 2000 Jul;25(3):324-8
references.pmid: 10888883
references.citation: Trends Mol Med. 2001 Nov;7(11):507-12
references.pmid: 11689336
references.citation: J Clin Oncol. 2005 Mar 10;23(8):1782-90
references.pmid: 15755986
references.citation: J Am Soc Nephrol. 2002 Jan;13(1):260-264
references.pmid: 11752046
references.citation: Bioinformatics. 2005 Jan 15;21(2):263-5
references.pmid: 15297300
references.citation: Asian Pac J Cancer Prev. 2012;13(2):479-82
references.pmid: 22524810
references.citation: Immunogenetics. 2006 Apr;58(2-3):107-12
references.pmid: 16508738
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references.pmid: 11553815
references.citation: Int J Cancer. 1996 Sep 27;68(1):8-13
references.pmid: 8895532
references.citation: Ann Neurol. 2005 Mar;57(3):373-80
references.pmid: 15732116
references.citation: Cytokine. 2012 May;58(2):261-6
references.pmid: 22370607
references.citation: Cancer Causes Control. 2000 Jul;11(6):533-42
references.pmid: 10880035
references.citation: Clin Biochem. 2010 Sep;43(13-14):1090-5
references.pmid: 20621078
references.citation: Hum Mol Genet. 2006 Oct 1;15(19):2955-61
references.pmid: 16940309
references.citation: Curr Opin Struct Biol. 2004 Feb;14(1):10-20
references.pmid: 15102444
references.citation: DNA Cell Biol. 2008 Oct;27(10):569-74
references.pmid: 18613756
references.citation: Cancer Res. 2002 Jun 15;62(12):3369-72
references.pmid: 12067976
references.citation: J Surg Oncol. 2006 Dec 1;94(7):624-30
references.pmid: 17111394
references.citation: Eur J Immunogenet. 2004 Aug;31(4):167-73
references.pmid: 15265021
references.citation: Nat Genet. 2001 Apr;27(4):435-8
references.pmid: 11279528
references.citation: Reprod Biomed Online. 2008 May;16(5):720-3
references.pmid: 18492378
references.citation: Gene. 2003 Jul 17;312:207-13
references.pmid: 12909357
references.citation: Stroke. 2011 Sep;42(9):2393-402
references.pmid: 21737794
references.citation: Mol Biol Rep. 2011 Apr;38(4):2417-25
references.pmid: 21080079
references.citation: Oncogene. 1998 Jul 16;17(2):227-36
references.pmid: 9674707
references.citation: Asian Pac J Cancer Prev. 2012;13(6):2879-86
references.pmid: 22938477
references.citation: Cancer Res. 2003 Feb 15;63(4):812-6
references.pmid: 12591731
references.citation: Eur J Immunogenet. 2003 Feb;30(1):1-3
references.pmid: 12558813
references.citation: Genetics. 2000 Nov;156(3):1259-75
references.pmid: 11063700
references.citation: Oncologist. 2010;15(6):556-65
references.pmid: 20507889
references.citation: Am J Hum Genet. 2000 Oct;67(4):881-900
references.pmid: 10986041
references.citation: Curr Opin Lipidol. 2010 Feb;21(1):38-43
references.pmid: 19915462
references.citation: FEBS Lett. 2006 May 22;580(12):2879-87
references.pmid: 16631753